SCHEMBL21541002

SCHEMBL21541002

CC(C)C(=O)[C@H](CCCNC(=N)N)N(C)C

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.34
CHRNB2 P17787 2/20 0.33
CHRNB4 P30926 2/20 0.33
CHRNA4 P43681 2/20 0.33
MEN1 O00255 1/20 0.33
CYP1A2 P05177 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPY4R P50391 7/20 0.32
NPY1R P25929 5/20 0.32
NPY2R P49146 3/20 0.32
NPY5R Q15761 3/20 0.32
ALB P02768 1/20 0.31
ITGB3 P05106 1/20 0.31
ITGA2B P08514 1/20 0.31
NOS3 P29474 1/20 0.30
NOS1 P29475 1/20 0.30
NOS2 P35228 1/20 0.30
CHRNA3 P32297 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24917432 0.95 ALOX15 (0.36) ALOX15CHRNB2CHRNB4CHRNA4MEN1
SCHEMBL20100650 0.88 ALOX15 (0.36) ALOX15CHRNB2CHRNB4CHRNA4MEN1
SCHEMBL26390131 0.87 ALOX15 (0.32) ALOX15MEN1CYP1A2KMT2ASMN1; SMN2
SCHEMBL9952942 0.85 ALOX15 (0.37) ALOX15CHRNB2CHRNB4CHRNA4MEN1
SCHEMBL9952753 0.85 ALOX15 (0.37) ALOX15CHRNB2CHRNB4CHRNA4MEN1
SCHEMBL288819 0.84 NOS2 (0.38) ALOX15CHRNB2CHRNB4CHRNA4MEN1
SCHEMBL196827 0.84 NOS2 (0.38) ALOX15CHRNB2CHRNB4CHRNA4MEN1
SCHEMBL29770073 0.84 NOS2 (0.38) ALOX15CHRNB2CHRNB4CHRNA4MEN1
SCHEMBL160690 0.84 NOS2 (0.38) ALOX15CHRNB2CHRNB4CHRNA4MEN1
SCHEMBL995563 0.84 NOS2 (0.38) ALOX15CHRNB2CHRNB4CHRNA4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780900-B2 Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof Janssen Sciences Ireland Unlimited Company (IE) 2023-10-10 US disclosed
US-11767354-B2 Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors JANSSEN PHARMACEUTICA NV (BE) 2023-09-26 US disclosed
US-11732019-B2 Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors JANSSEN PHARMACEUTICA NV (BE) 2023-08-22 US disclosed
US-20210253661-A1 GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF Janssen Sciences Ireland Unlimited Company (IE) 2021-08-19 US disclosed
US-20210163566-A1 Antibody-Coupled Cyclic Peptide Tyrosine Tyrosine Compounds as Modulators of Neuropeptide Y Receptors JANSSEN PHARMACEUTICA NV (BE) 2021-06-03 US disclosed
US-10875902-B2 Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2020-12-29 US disclosed
US-20190330296-A1 GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2019-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210253661-A1 GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF GLP1R, GIPR, IAPP ALOX15 4087/4885CHRNB2 2651/4885CHRNB4 2573/4885
US-10875902-B2 Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof GLP1R, GIPR, IAPP ALOX15 4087/4885CHRNB2 2651/4885CHRNB4 2573/4885
US-11732019-B2 Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors NPY4R, NPY5R, NPY1R ALOX15 1793/4885CHRNB2 1565/4885CHRNB4 1000/4885
US-11780900-B2 Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof GLP1R, GIPR, IAPP ALOX15 4087/4885CHRNB2 2651/4885CHRNB4 2573/4885
US-20210163566-A1 Antibody-Coupled Cyclic Peptide Tyrosine Tyrosine Compounds as Modulators of Neuropeptide Y Receptors NPY1R, NPY5R, NPY2R ALOX15 2953/4885CHRNB2 678/4885CHRNB4 643/4885
US-11767354-B2 Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors NPY1R, NPY5R, NPY2R ALOX15 2953/4885CHRNB2 678/4885CHRNB4 643/4885
US-20190330296-A1 GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF GLP1R, GIPR, IAPP ALOX15 4087/4885CHRNB2 2651/4885CHRNB4 2573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.